Swedish Saromics Biostructures join forces with Swiss Bioversys to fight against multidrug-resistant bacterial infections.
The two companies will collaborate in an international project supported by the European initiative Eurostars. Saromics Biostructures and Bioversys will combine technology modules, expertise and resources to drive the drug development process of initial hit molecules towards fully characterized lead molecules that qualify for preclinical testing. Part of the project will according to Saromics Biostructures be financed by a Eurostars grant.
The Eurostars program supports research-performing small and medium enterprises, which develop innovative products, processes and services, to gain competitive advantage. Eurostars provides funding for transnational innovation projects where projects have partners from two or more Eurostars countries. The program is publically financed with a total budget of 1.14 billion euro and is currently supported by 33 EUREKA countries and the European Union.